Table 2.
VDR-FokI polymorphism in study subjects analyzed with respect to GAD65 antibody status
| GAD65-positive | GAD65-negative | Controls | |
| T1DM | T1DM | ||
| n = 48 | n = 30 | n = 250 | |
| Genotype frequenciesa | |||
| FF | 26 (54%) | 10(33%) | 82 (33%) |
| Ff | 19 (40%) | 18(60%) | 138 (55%) |
| ff | 3(6%) | 2(7%) | 30 (12%) |
| Allele frequenciesb | |||
| F | 71 (74%) | 38(63%) | 302(60%) |
| f | 25 (26%) | 22(37%) | 198(40%) |
| Phenotype frequenciesc | |||
| F positive | 45 (94%) | 28 (94%) | 220(88%) |
| f positive | 22 (46%) | 20 (67%) | 168(67%) |
Values shown are the number of subjects with the percentage in parentheses. aΧ2 test of heterogeneity between GAD65-positive T1DM patients and control subjects. Χ2 = 8.14, 2 degrees of freedom; P = 0.017. bΧ2 test of heterogeneity between GAD65-positive T1DM patients and control subjects. Χ2 = 6.32, 1 degree of freedom; P = 0.012. cRelative risk ratio for F phenotype (GAD65-positive T1DM) = 2.0.